Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Veraxa Biotech Holding AG's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was $28.90 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $66.83 Mil.
Veraxa Biotech Holding AG (NAS:VRXA) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Veraxa Biotech Holding AG Selling, General, & Admin. Expense Related Terms
Veraxa Biotech Holding AG Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Veraxa Biotech Holding AG's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG Selling, General, & Admin. Expense Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
Selling, General, & Admin. Expense
12.20
23.25
67.60
Veraxa Biotech Holding AG Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Selling, General, & Admin. Expense
0.00
8.52
14.71
37.93
28.90
VRXA vs TTRX, IRD, IFRX: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's Selling, General, & Admin. Expense falls into.
Veraxa Biotech Holding AG Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $66.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $66.83 Mil mean?
Veraxa Biotech Holding AG (VRXA) has a Selling, General, & Admin. Expense of $66.83 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Selling, General, & Admin. Expense too high?
Veraxa Biotech Holding AG's current Selling, General, & Admin. Expense is $66.83 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Selling, General, & Admin. Expense compare to TTRX and IRD?
Veraxa Biotech Holding AG's Selling, General, & Admin. Expense of $66.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Selling, General, & Admin. Expense is $66.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Selling, General, & Admin. Expense of $66.83 Mil. The current Selling, General, & Admin. Expense is $66.83 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Selling, General, & Admin. Expense is $66.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
